Last €70.62 EUR
Change Today +0.13 / 0.18%
Volume 68.5K
As of 1:55 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

morphosys ag (MOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/28/14 - €74.90
52 Week Low
11/13/13 - €50.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MORPHOSYS AG (MOR)

Related News

No related news articles were found.

morphosys ag (MOR) Related Businessweek News

No Related Businessweek News Found

morphosys ag (MOR) Details

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

Founded in 1992

morphosys ag (MOR) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €772.6K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €524.1K
Chief Development Officer and Member of Manag...
Total Annual Compensation: €524.1K
Chief Scientific Officer and Member of Manage...
Total Annual Compensation: €524.1K
Compensation as of Fiscal Year 2013.

morphosys ag (MOR) Key Developments

Emergent BioSolutions, Inc. and Morphosys AG Announce Agreement for Joint Development and Commercialization of Emergent's Preclinical Bi-Specific Antibody, ES414, Targeting Prostate Cancer

Emergent BioSolutions Inc.and MorphoSys AG announced an agreement for the joint development and commercialization of Emergent's preclinical bi-specific antibody, ES414, targeting prostate cancer. Under the terms of the agreement, Emergent will receive an upfront payment of USD 20 million and milestone payments of up to USD 163 million. These milestone payments are linked to specific events, including successful development of ES414 in several indications and securing approval in certain territories. Emergent and MorphoSys will jointly develop ES414, with MorphoSys bearing 64% and Emergent 36% of the total costs. Emergent will retain commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, from mid-single digit up to 20%. MorphoSys will gain worldwide commercialization rights excluding the U.S. and Canada, with a low single digit royalty obligation to Emergent. Emergent will manufacture and supply clinical material from its manufacturing facilities in Baltimore, Maryland. Additional financial details were not disclosed.

Morphosys AG - Special Call

To present more information on an agreement for the joint development and commercialization of MOR209/ES414

Morphosys AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Re-Confirms Earnings Guidance for the Year 2014

Morphosys AG reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company generated revenues from continuing operations in the amount of EUR 14.7 million, compared to EUR 31.3 million in the same quarter of 2013. The main reason for the revenue decrease was the license agreement with GlaxoSmithKline for MorphoSys's clinical antibody program MOR103 in second quarter of 2013. LBIT was EUR 1 million compared to EBIT of EUR 14.8 million a year ago. Net loss was EUR 0.5 million compared to net profit of EUR 11.1 million a year ago. For the six months, the company’s revenues were EUR 30.5 million compared to EUR 48.2 million a year ago. Reasons for the decrease of 37 % were one-time effects in H1 2013 in connection with the license agreement with GlaxoSmithKline for MOR103 as well as the license payment from Bio-Rad in connection with their acquisition of MorphoSys's AbD Serotec segment. EBIT was EUR 0.4 million compared to EUR 17.3 million a year ago. Profit from continuing operations was EUR 0.6 million compared to EUR 13 million a year ago. Consolidated net profit was EUR 0.6 million or EUR 0.02 per diluted share compared to EUR 19 million or EUR 0.81 per diluted share a year ago. The company re-confirmed its guidance for 2014, the company anticipates total Group revenues of EUR 58 million to EUR 63 million and anticipates a negative EBIT in the range of EUR 11 to EUR 16 million in 2014. The company's management anticipates the LBIT to be at the EUR 11 million level.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOR:GR €70.62 EUR +0.13

MOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $168.22 USD +1.75
Intrexon Corp $20.09 USD +0.34
XOMA Corp $4.24 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation MOR Industry Range
No financial data is available for MOR.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MORPHOSYS AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at